Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related phenomenon that occurs when hematopoietic stem cells acquire mutations in a select set of genes commonly mutated in myeloid neoplasia which then expand clonally. Current sequencing assays to detect CHIP are not optimized for the detection of these variants and can be cost-prohibitive when applied to large cohorts or serial sequencing. Here, we present and validate a CHIP targeted sequencing assay that is affordable (∼$8/sample), accurate and highly scalable. To demonstrate the utility of this assay, we detected CHIP in a cohort of 456 individuals with DNA collected at multiple timepoints in the Vanderbilt BioVU biobank and quantified clonal expansion rates over time. A total of 101 individuals with CHIP were identified, and individual-level clonal expansion rate was calculated using the variant allele fraction (VAF) at both timepoints. Differences in clonal expansion rate by driver gene were observed, but there was also significant individual-level heterogeneity, emphasizing the multifactorial nature of clonal expansion. We further describe the mutation co-occurrence and clonal competition between multiple driver mutations.
Competing Interest Statement
MRS: Advisory board or Consultancy: Bristol Myers Squibb CTI, Forma, Geron, GSK/Sierra Oncology, Karyopharm, Ryvu Therapeutics, Taiho Pharmaceutical, Research funding: ALX Oncology, Astex Pharmaceuticals, Incyte Corporation, Takeda, TG Therapeutics; Equity holder: Empath Biosciences, Karyopharm, Ryvu Therapeutics; Travel expenses: Astex. AGB: Advisory board & Equity holder: TenSixteen Bio.
Funding Statement
A.J.S. received financial support from the US National Institutes of Health under a Ruth L. Kirschstein National Research Service Award F30DK127699 from the NIDDK and T32GM007347 from the NIGMS. MRS is a Leukemia and Lymphoma Clinical Scholar, and receives funding from the Biff Ruttenberg Foundation, Adventure Alle Fund, Beverly and George Rawlings Endowment, and the NIH 1R01 CA262287-01 and U01 OH012271 01. AGB is supported by NIH DP5 OD029586, a Burroughs Wellcome Fund Career Award for Medical Scientists, the E.P. Evans Foundation, RUNX1 Research Program, a Pew Stewart Scholar for Cancer Research award, supported by the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust, the Vanderbilt University Medical Center Brock Family Endowment and Young Ambassador Award. The Vanderbilt Ingram Cancer Center is supported by a NIH P30 CA068485 19.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Vanderbilt Human Research Protection Program Health Sciences Committee 1, Institutional Review Board OHRP Registration Identification (IRB00000475) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
